Incannex Healthcare (IXHL) Long-Term Investments (2020 - 2026)

Incannex Healthcare (IXHL) posted quarterly Long-Term Investments of $27000.0 for Q1 2026, down 52.63% on a QoQ basis from $57000.0 in Q4 2025.

Incannex Healthcare (IXHL) Long-Term Investments (2020 - 2026) Analysis & Trends

Incannex Healthcare (IXHL) has reported Long-Term Investments for 3 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.

Quarterly Long-Term Investments changed N/A year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27000.0 (changed N/A YoY) and the FY2020 annual result came in at $29277.0, changed N/A from the prior year.
Long-Term Investments eased to $27000.0 in Q1 2026 per IXHL's latest filing, from $57000.0 in the prior quarter.
Over the last five years, Long-Term Investments for IXHL reached as high as $57000.0 in Q4 2025 and fell as low as $27000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	56.09 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	1.32 Bn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	702.35 Mn
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	146.10 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Incannex Healthcare	3.63 Mn	3.63 Mn	-	27,000.00

Download Data